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Introduction: This is the first report of which the authors are aware to describe this c.2166delinsGG mutation in
X-linked hypophosphataemia and to describe normalisation of renal threshold for phosphate excretion after
parathyroidectomy for tertiary hyperparathyroidism in X-linked hypophosphataemia.
Case presentation: We present the case of a 34-year-old Caucasian woman with X-linked hypophosphataemia.
She developed tertiary hyperparathyroidism with markedly high bone turnover requiring total parathyroidectomy
and had prolonged requirement for intravenous calcium infusion after surgery. She had a novel mutation in her
phosphate-regulating gene with homologies to endopeptidases on the X-chromosome and had an unusual degree
of dependence on phosphate supplementation. Prior to operative intervention she had a trial of cinacalcet that
improved bone turnover markers when used in isolation but which led to a paradoxical rise in parathyroid hormone
levels when given with phosphate supplementation. After correction of hungry bone syndrome, the renal
phosphorus threshold normalised as a manifestation of hypoparathyroid state despite marked elevation in level
of fibroblast growth factor 23.
Conclusions: This case illustrates the risk of tertiary hyperparathyroidism as a complication of treatment for
hypophosphataemia; it highlights the morbidity associated with hungry bone syndrome and provides novel insight
into renal handling of phosphorus.
Keywords: Cinacalcet, Fibroblast growth factor 23, Hungry bone syndrome, Hyperparathyroidism, X-linked
hypophosphataemiaIntroduction
X-linked hypophosphataemia (XLH) is a congenital
cause of renal phosphorus wasting as a consequence of
inactivating mutations in the phosphate-regulating gene
with homologies to endopeptidases on the X chromo-
some (PHEX) that manifests with rickets and poor linear
growth in childhood [1]. It has an X-linked dominant
inheritance and the disease severity is variable; it is asso-
ciated with increased bone expression of fibroblast
growth factor 23 (FGF23) that mediates both the renal* Correspondence: mjmckenn@iol.ie
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reproduction in any medium, provided the orphosphorus wasting and the impaired activation of vita-
min D to its hormonal form [1]. In childhood, it is
treated by a combination of phosphorus supplements
and activated forms of vitamin D, but judicious use of
phosphorus is advised in order to prevent hyperpara-
thyroidism [2].
We present the case of a woman with XLH who pre-
sented to adult services with evidence of tertiary hyper-
parathyroidism. We discuss the challenges in management
of progressive severe hyperparathyroidism over a 16-year
period and the unlikely benefit of the renal phosphorus
handling by rendering her hypoparathyroid despite very
high FGF23 levels.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Bone turnover markers pre- and post-parathyroidectomy.
Top panel: Serial changes prior to parathyroidectomy in bone
resorption marker (urinary N-terminal cross-linking telopeptide of type I
collagen) and a bone formation marker (serum procollagen type-I
N-propeptide. Lower panel: Serial changes after parathyroidectomy in
bone resorption markers (urinary C-terminal cross-linking telopeptides)
and a bone formation marker (serum procollagen type-I N-propeptide).
Reference ranges are denoted by stippled boxes along vertical axes.
Abbreviations: BTM, bone turnover markers; CTxurinary C-terminal
cross-linking telopeptides; mMCr, mmol creatinine; nMBCE, nmol Bone
Collagen Equivalents; NTx, urinary N-terminal cross-linking telopeptide of
type I collagen; PINP, serum procollagen type-I N-propeptide.
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A 34-year-old Caucasian woman initially presented to
the paediatric service at 19 months of age with difficulty
walking and a broad-based gait, and was noted to be
hypophosphataemic. She was commenced on vitamin D
and phosphate replacement. On this treatment, she had
normal growth and puberty, but had frontal bossing and
enamel hyperplasia of her teeth. Her mature height was
158cm and her weight was 85.6kg. After transfer to the
adult service, genetic testing identified a novel deletion-
insertion mutation (c.2166delinsGG) in exon 22 of her
PHEX gene; the mutation resulted in a premature ter-
mination at codon 725. Over the next 17 years, serial
measurements were made of indices of calcium metabol-
ism and bone turnover markers using previously de-
scribed techniques [3].
At the time of presentation to adult services she had
evidence of tertiary hyperparathyroidism, with ionised
calcium of 1.38mmol (reference range 1.19 to 1.35), and
parathyroid hormone (PTH) of 454pg/mL (reference
range 12 to 64). She was being treated with phosphorus
supplementation in adulthood, of up to six tablets daily
of Phosphate-Sandoz® 96mmol (or 3g of phosphorus);
1α-hydroxyvitamin D had been stopped due to hypercal-
caemia. Attempts to reduce phosphorus supplementa-
tion failed because of muscle cramps and fatigue at
lower doses. Over the next 7 years her clinical condition
remained relatively stable, although monitoring of
ionised calcium and PTH indicated that tertiary hyper-
parathyroidism continued to progress. Serial measure-
ment of both a bone resorption marker, urinary N-terminal
cross-linking telopeptide of type-I collagen, and a formation
marker, procollagen type-I N-propeptide (PINP), were
made throughout this time [3]; both levels rose steadily
(Figure 1). When hypercalcaemia recurred (ionised calcium
1.57mmol/L, PTH 1107pg/mL), she agreed to stop phos-
phorus supplementation and to take a trial of cinacalcet
therapy, starting at a dose of 30mg increasing to 60mg per
day. Both ionised calcium (1.22mmol/L) and PTH (360pg/
mL) dropped and bone turnover markers were reduced.
However, she became wheelchair-bound secondary to my-
opathy that resolved on restarting phosphorus supplemen-
tation and ceasing cinacalcet. Cinacalcet was re-introduced
with phosphorus after her clinical status improved, but this
combination of therapies resulted in a paradoxical response
(ionised calcium 1.21mmol/L but PTH 1084pg/mL) with
concomitant surge in bone turnover markers to very high
levels (Figure 1, age 27 to 28 years). In view of this
PTH-mediated excess bone turnover, cinacalcet was dis-
continued. At this stage she complained of diffuse aches
and pains.
Given the severity of parathyroid bone disease, persist-
ent hypercalcaemia, and evidence of a slow deterioration
in renal function with estimated glomerular filtrationrate (eGFR) ranging from 59 to 80mL/minute/1.72m2 ,
(Modified Diet in Renal Disease method) it was decided
to proceed with total parathyroidectomy. Since she was
considered to be at high risk of severe hungry bone syn-
drome after parathyroidectomy, she was admitted prior
to surgery for treatment with intravenous zoledronic
acid that resulted in three separate adverse reactions: an
acute phase response; a hypersensitivity response with
mild angioedema followed by hepatic transaminitis, both
of which responded to a short course of oral steroids;
and symptomatic hypocalcaemia with total calcium
1.66mmol/L, necessitating intravenous calcium infusion.
In view of the hypersensitivity response, this strategy of
preparing the patient for total parathyroidectomy was
abandoned. Admission for total parathyroidectomy was
planned, with high-dependency admission for manage-
ment of anticipated hungry bone syndrome.
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glands were enlarged, ranging in weight from 2.5 to 3.4g.
Successful resection was confirmed by undetectable
PTH levels. Persistent hypocalcaemia followed, necessi-
tating intravenous calcium infusion as a hospital in-
patient for 160 days post-surgery. A peripherally inserted
central catheter line was placed and she was infused
with 10% calcium gluconate solution to maintain total
calcium over 1.9mmol/L. The total volume infused was
42,360mL, which was equivalent to 356g of elemental
calcium. On discharge from hospital she was treated
with 1α-vitamin D 6μg/day and oral calcium 2000mg
daily; she no longer required phosphorus supplements.
Her bone turnover response was monitored in the
postoperative period by measuring serum PINP and
serum C-terminal cross-linking telopeptides (CTx). One
year after surgery both PINP and CTx had returned to
the normal reference range (Figure 1). Over the same
time period she experienced a dramatic increase in bone
mineral density (BMD): spine BMD increased by 68% up
to Z-score of 7.2; and total hip BMD increased by 57%
up to a Z-score of 5.2. Her gain in BMD and the reduc-
tion in CTX with increase in PINP reflects a prolonged
spell of positive remodelling balance after total parathy-
roidectomy. Her theoretical renal phosphorus absorption
threshold per glomerular filtrate (TmP/GF) increased
from a low level to within the normal range (Figure 2).
Her serum FGF23 was markedly elevated at 4790RU/mL
(reference less than 100RU/mL); the level had not been
measured preoperatively. Her postoperative course was
















Figure 2 Serial changes in renal phosphorus handling before and afte
phosphorus absorption threshold per glomerular filtrate.subsequently stabilised at an estimated GFR of 39mL/
minute. There was no evidence of nephrocalcinosis.
Discussion
The metabolic defect in XLH is an impairment of phos-
phorus reabsorption at the proximal tubule of the kidney
and the underlying mutation is a loss of function of the
PHEX gene [4]. Loss of function in PHEX is associated
with increased circulating FGF23 which acts to reduce
expression of sodium-phosphate co-transporters (NaPi)
in the renal tubule in association with its co-factor
Klotho, and to reduce 1α-hydroxylase activity [5,6]; the
link between PHEX activity and FGF23 levels remains
unclear. In childhood and adolescent cases with XLH,
conventional treatment is with activated vitamin D and
phosphorus [2]. Normalisation of serum phosphorus
concentration is not an aim and is likely to result in sec-
ondary hyperparathyroidism [2].
High PTH leads to increased phosphorus excretion
and thus increased requirement for supplementation;
once this cycle has been initiated it is difficult to reverse.
Tertiary hyperparathyroidism in XLH has been well
described [7] and is thought to result from chronic
stimulation of PTH by phosphorus supplements, leading
to autonomous secretion from hyperplastic or adenoma-
tous parathyroid glands [8]. In a previous case series
by Savio et al. of patients with XLH who underwent
parathyroidectomy for tertiary hyperparathyroidism, five
of the six patients required either a one- or two-step
total parathyroidectomy, with only one patient undergo-
ing re-implantation of parathyroid tissue; and foure (years)
30 35
rus Handling
r parathyroidectomy. Abbreviations: TmP/GF, theoretical renal
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though the most prolonged dependence on intravenous
calcium was for 15 days [8]. The authors of the surgical
case series also commented that postoperative hypopara-
thyroidism was a second insult to patients who already
had mineral deficiencies from their inability to re-absorb
phosphate; in our patient, TmP/GF normalised after
parathyroidectomy. In Albright’s original description of
XLH, one patient experienced transient normalisation of
serum phosphorus after surgical excision of a hyperplas-
tic parathyroid gland [9]. The normalisation of phos-
phate excretion in our patient may be due to the
reduction in renal function; normalisation of TmP/GF
has been reported in a patient with XLH with chronic
kidney disease (CKD) previously [10]. However, a sud-
den dramatic rise in TmP/GF such as that of our patient
(Figure 2) is not usually seen in CKD. The lack of
requirement for phosphate supplementation in the hypo-
parathyroid state suggests that the presence of circulat-
ing PTH may be necessary for FGF23 to exert its
phosphaturic action; this is in keeping with observations
in the Hyp mouse with targeted deletion of the PTH
gene [11]. Improvement in TmP/GF has been shown in
patients with XLH receiving phosphorus who had a re-
duction in PTH on cinacalcet therapy [12].
Careful supplementation of phosphorus and vitamin D
in childhood is necessary to optimise growth and to pre-
vent development of tertiary hyperparathyroidism and
renal impairment [2]. Phosphorus therapy is associated
with diarrhoea and is a stimulant to PTH secretion [13]
as well as FGF23 secretion [14]; it is associated with
nephrocalcinosis in treated patients with XLH [15] and
thus normalisation of serum phosphorus is not the tar-
get of therapy in XLH [2]. Vitamin D supplementation is
associated with hypercalciuria [15], hence monitoring of
urinary as well as serum calcium is necessary to assess
whether vitamin D dosage should be reduced.
After development of tertiary hyperparathyroidism,
therapeutic options become more limited. Clearly surgi-
cal management carries a high risk of hungry bone syn-
drome, and the benefits of total parathyroidectomy which
might lead to an adynamic bone state must be weighed
against the possibility of treatment failure if auto-
transplant with a parathyroid fragment is attempted. Cina-
calcet therapy may be of benefit; in other patient series
phosphorus therapy was not discontinued and the para-
doxical PTH rise experienced by our patient was not re-
ported [16].
Conclusions
This case report illustrates the challenges of manage-
ment of XLH after tertiary hyperparathyroidism has
developed, and supports improved liaison between paedi-
atric and adult endocrine and rheumatology services tooptimise care and prevent development of iatrogenic com-
plications. The case also suggests a potential role for PTH
in the phosphaturic action of FGF23, which will be of
interest to endocrinologists and nephrologists.
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